Literature DB >> 31371152

Endophthalmitis reduction with intracameral moxifloxacin in eyes with and without surgical complications: Results from 2 million consecutive cataract surgeries.

Aravind Haripriya1, David F Chang2, Ravilla D Ravindran3.   

Abstract

PURPOSE: To analyze the posterior capsule rupture (PCR) rates among staff and trainee cataract surgeons, and the postoperative endophthalmitis (POE) rates in uncomplicated and complicated eyes both with and without intracameral moxifloxacin prophylaxis (ICMP).
SETTING: Ten regional Aravind Eye Hospitals in India.
DESIGN: Retrospective multicenter clinical registry within a single hospital network.
METHODS: POE rates with and without ICMP were statistically compared for all eyes and separately for trainees versus staff, for phacoemulsification versus manual small-incision cataract surgery (M-SICS), and for a subgroup of eyes complicated by PCR or requiring secondary surgery.
RESULTS: All cataract surgeries (2 062 643) performed during the 8-year period from 2011 to 2018 at the 10 regional Aravind Eye hospitals were included in the analysis. With ICMP, the overall POE rate declined from 692 (0.07%) of 993 009 eyes to 185 (0.02%) of 1 069 634 eyes (P < .001). This was independently significant for phacoemulsification and for M-SICS (P < .001). The overall PCR rate was 28 352 (1.37%) of 2 062 643 eyes, and it was statistically higher for trainees irrespective of surgical method (P < .001). Both staff and trainee surgeons had higher PCR rates with phacoemulsification than with M-SICS (P < .001). Absent ICMP, PCR increased the overall POE rate by more than 7-fold to 63 (0.43%) of 14 505 eyes. ICMP reduced the POE rate after PCR to 25 (0.18%) of 13 847 eyes (P = .002). This ICMP benefit was separately significant for both M-SICS (0.54% vs 0.26%, P = .01) and phacoemulsification (0.29% vs 0.06%, P = .005). The POE rate was especially high after secondary IOL implantation (0.90% without ICMP vs 0.34% with ICMP; P = .10).
CONCLUSIONS: ICMP reduced the POE rate overall, with phacoemulsification, with M-SICS, and in eyes with PCR.
Copyright © 2019 ASCRS and ESCRS. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31371152     DOI: 10.1016/j.jcrs.2019.04.018

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  7 in total

1.  Three Learning Organizations in Cataract Surgery: The Example of Intracameral Antibiotic Injection.

Authors:  Neal H Shorstein; Per Montan; Aravind Haripriya; Mats Lundström; Lisa Herrinton
Journal:  Perm J       Date:  2021-05-19

2.  Prophylactic antibiotics for postcataract surgery endophthalmitis: a systematic review and network meta-analysis of 6.8 million eyes.

Authors:  Ai Kato; Nobuyuki Horita; Ho Namkoong; Eiichi Nomura; Nami Masuhara; Takeshi Kaneko; Nobuhisa Mizuki; Masaki Takeuchi
Journal:  Sci Rep       Date:  2022-10-18       Impact factor: 4.996

Review 3.  Drop-free approaches for cataract surgery.

Authors:  Neal H Shorstein; William G Myers
Journal:  Curr Opin Ophthalmol       Date:  2020-01       Impact factor: 4.299

4.  Endophthalmitis Prophylaxis Failures in Patients Injected With Intracameral Antibiotic During Cataract Surgery.

Authors:  Neal H Shorstein; Liyan Liu; James A Carolan; Lisa Herrinton
Journal:  Am J Ophthalmol       Date:  2021-02-08       Impact factor: 5.488

5.  Needless Waste and the Sustainability of Cataract Surgery.

Authors:  David F Chang
Journal:  Ophthalmology       Date:  2020-07-15       Impact factor: 12.079

6.  Visual and Refractive Outcomes of Cataract Surgeries Performed in One Year in a Private Practice Setting: Review of 2714 Procedures.

Authors:  Laureano A Rementería-Capelo; Jorge L García-Pérez; Juan Gros-Otero; Aida Morán; José M Sánchez-Pina; Inés Contreras
Journal:  J Ophthalmol       Date:  2020-04-14       Impact factor: 1.909

7.  Postoperative endophthalmitis with and without intracameral moxifloxacin prophylaxis in a high volume surgery setting.

Authors:  Subash Bhatta; Nayana Pant; Manish Poudel
Journal:  BMJ Open Ophthalmol       Date:  2021-06-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.